ClinicalTrials.gg
Status unknownNCT03701672ABILITY-2Updated Oct 10, 2018

Identification of Predictive Markers of the Effects of Opioid Therapy in Patients With Chronic Pain.

An observational study in Chronic Pain, sponsored by Asbjørn Mohr Drewes. Status unknown at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-10.

Sponsored by Asbjørn Mohr Drewes · Observational

How we know

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Chronic Pain with a site in Denmark — 14 open to participants now, 16 under way, none of them phase 3. Chronic Pain · Denmark.

Planned enrollment
23rd of 33
60 · median 134
Started
2018
with 4 others
Observational
33 of 90
6 open now
Registered
44th of 90
by date

Among the 90 studies in Chronic Pain with a site in Denmark, this one is the 23rd largest by planned enrollment of the 33 observational ones that give a count, is one of 5 that started in 2018, is one of 33 observational ones, and was the 44th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

14 of the 90 studies in Chronic Pain with a site in Denmark are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Chronic Pain with a site in Denmark, or all of them as a file.
02

Study summary

Chronic pain is a significant problem for a large part of the adult population. Opioids are the mainstay of therapy for moderate to severe pain because of their safety, multiple routes of administration, reliability, and effectiveness for all types of pain. However, there is a wide variation in treatment response and a high frequency of side effects associated with the use of opioids. Thus it is important to identify patients who will experience successful pain control with treatment. Unfortunately, as of today no robust objective measures exist for the assessment of the pain-relieving effect of opioids. The pain treatment offered to any given patient is thus largely dependent on the treating physician's experience and the primary pain diagnosis, rather than the characteristics of the individual patient. Unfortunately, this strategy often leads to inadequate treatment, side effects and distress. An implementable clinical tool that can predict and distinguish successful pain control with opioid treatment is therefore warranted.

Quantitative sensory testing (QST) is a method to evaluate the individual pain system. It has been successfully used to describe the problems of individual variation in pain and to predict and measure the responses to an intervention. The investigators recently examined how advanced analyses of QST and pain-related catastrophic thinking could predict opioid response in chronic pain patients whom had not previously received opioid treatment. This study showed that the effect of opioid treatment was predicted by certain pain system responses, catastrophic thinking related to pain and brainwave patterns. The investigators now want to expand on this study by including all patients assigned to opioid treatment by their treating physician. The investigators are also increasing their data collection and using a more elaborate pain system characterization, investigating pain-relevant psychological factors and sleep patter by questionnaires, socio-demographic parameters and collecting descriptive genetic information.

The overall goal of the ABILITY-2 study is to help improve pain diagnostics and treatment by developing an implementable algorithm based on individual patient characteristics to be used in the clinic. The investigators hypothesize that successful pain control with opioids can be predicted before treatment initiation with advanced analyses of QST, pain-related psychological factors and socio-demographic data.

03

Conditions studied

  • Chronic Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants referred tol treatment at a Multidisciplinary Pain Clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pain duration ≥ 3 months.
  2. Minimum baseline pain intensity ≥ 4 on a 0-10 numerical rating scale (over the past week).
  3. Maximum baseline pain intensity \< 9 on a 0-10 numerical rating scale (over the past week).
  4. Prescribed opioid treatment (ATC: N02)
  5. Anticipated to stay on prescribed opioid treatment throughout the study, i.e. >30 days.
  6. Anticipated to stay on any concomitant non-opioid treatment throughout the study, i.e. >30 days.
  7. Subject may be male or female, age >18 years old.
  8. Is willing and able to comply with study procedures as judged by the site investigator.
  9. Subject has voluntarily signed and dated the study-specific form, approved by an Independent Ethics Committee, after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent form must be signed before any study-specific procedures are performed.

Exclusion criteria

Exclusion Criteria:

  1. Has a mental incapacity or language barriers precluding adequate understanding of study procedures.
  2. Is considered by the site investigator unsuitable to participate in the study for any other reason, for instance due to a significant serious underlying condition.
  3. Current alcohol or substance abuse, according to the site investigator's medical judgement.
  4. Are suffering from decreased liver function, kidney function, uncontrolled hypertension or currently in treatment with monoamine oxidate (MAO)-inhibitors
  5. Is anticipated to undergo a painful procedure(s) (e.g. surgery) during the study, which can interfere with the experience of the chronic pain condition for which the subject is to receive opioids.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
1 Month
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Opioid Analgesic Treatment

    Chronic paint patients receiving opioid treatment at a Multidisciplinary Pain Center following local SOPs

    Other: Opioid Analgesic Treatment

Interventions

  • OtherOpioid Analgesic Treatment

    Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).

06

What researchers measure

Primary outcomes

  1. Change in chronic pain assessed by 0-10 numerical rating scale (NRS) scores on the Brief Pain Inventory (BPI)

    The absolute and percentage change from baseline in ratings of average pain in the past 24h at Day 30. Of note, a percentage change of ≥30% is considered clinically significant. On the NRS, 0 reflects no pain and 10 reflecs worst pain imaginable in this experimental setup.

    Time frame: 30 days

  2. Change in health-related quality of life assessed by QLQ-C30 scores

    The absolute and percentage change from baseline in ratings of health-related quality of life in the past week at Day 30. A subjectively significant change in QLQ-C30 scores is one that is ≥10 from baseline.The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.

    Time frame: 30 days

Secondary outcomes

  1. Patient Global Impression of Change

    Patients impression of change reported as a 7 item assesment of change (1 = much worse and 7 = much better) and the importance of this change (1 = not at all important to 5= extremely important)

    Time frame: 30 days

  2. The Brief Pain Inventory (BPI) worst pain in the past 24h assessed by 0-10 numerical rating scale (NRS) scores

    Change from baseline. On the NRS, 0 reflects no pain and 10 reflecs worst pain imaginable in this experimental setup.

    Time frame: 30 days

  3. The Brief Pain Inventory (BPI) least pain in the past 24h assessed by 0-10 numerical rating scale (NRS) scores

    Change from baseline, On the NRS, 0 reflects no pain and 10 reflecs worst pain imaginable in this experimental setup.

    Time frame: 30 days

  4. The Brief Pain Inventory (BPI) current pain in the past 24h assessed by 0-10 numerical rating scale (NRS) scores

    Change from baseline, On the NRS, 0 reflects no pain and 10 reflecs worst pain imaginable in this experimental setup.

    Time frame: 30 days

  5. The Brief Pain Inventory (BPI) pain severity in the past 24h assessed by 0-10 numerical rating scale (NRS) scores

    Change from baseline, On the NRS, 0 reflects no pain and 10 reflecs worst pain imaginable in this experimental setup.

    Time frame: 30 days

  6. Severity of Adverse Events

    Total score of Adverse Events rated from 1-4 in severity, with 1 being "not at all" and 4 being "Very much". Following adverse events: Constipation, Dry mouth, Nausea/vomiting, Sedation Sweats Bad dreams, Dysphoria/delirium Sleep disturbances, Fatigue, Absent minded, Concentration difficulties, Depressed, Weight gain, Muscle tension, Urination difficulties Ich/Rash, Other

    Time frame: 30 days

07

Study locations

1 site
  • Aleris-Hamlet Hospital
    Ringsted, 4100, Denmark
    • Torsten Jonsson, MD · Contact
    • Torsten Jonsson, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2018; primary completion for Mar 2020, 17 months later.

Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 17 months is below that.

Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2018
First posted
Oct 10, 2018
StartEst.
Oct 2018
Primary completionEst.
Mar 2020
CompletionEst.
Mar 2020
Last update
Oct 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03701672
Lead sponsor
Asbjørn Mohr Drewes
Collaborators
Aleris-Hamlet Hospital, University of Copenhagen
Responsible party
Asbjørn Mohr Drewes (Professor, Aalborg University Hospital) — Sponsor-investigator
First posted
Oct 10, 2018
Start date
Oct 2018 (estimated)
Primary completion
Mar 2020 (estimated)
Completion
Mar 2020 (estimated)
Last update
Oct 10, 2018

Study contacts

Asbjørn M Drewes, MD
Contact
amd@rn.dk
0045 9766 3562
Asbjørn M Drewes, MD
study director · Aalborg University Hospital
Torsten Jonsson, MD
principal investigator · Aleris-Hamlet Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion